Evaluation of Apo A IV and Haptoglobin as Potential CSF Markers in Patients with Guillain-Barre´ Syndrome: A Cross-Sectional Study.
Journal
Neurology India
ISSN: 1998-4022
Titre abrégé: Neurol India
Pays: India
ID NLM: 0042005
Informations de publication
Date de publication:
01 May 2024
01 May 2024
Historique:
received:
07
01
2021
accepted:
27
04
2022
medline:
23
7
2024
pubmed:
23
7
2024
entrez:
23
7
2024
Statut:
ppublish
Résumé
Brain- and blood-derived protein analysis in the cerebro-spinal fluid (CSF) in various studies performed abroad found that some proteins and their isoforms were altered significantly in Guillain-Barre´ syndrome (GBS) patients in comparison to controls. However, data are lacking in India with respect to the blood- or brain-derived proteins in patients of GBS. This study aimed to identify the role of apolipoprotein A IV (Apo A IV) and haptoglobin as potential protein markers in CSF of patients with GBS in our population. The study comprised 28 participants where 12 confirmed cases of GBS and 16 control subjects admitted for non-infectious neurological disorders were recruited after obtaining approval from the Institutional Ethics Committee. CSF glucose, protein, and adenosine deaminase were analyzed using an autoanalyzer. The concentrations of Apo A IV and haptoglobin were estimated with enzyme-linked immuno-sorbent assay (ELISA) kits. The CSF protein concentrations of cases were higher as compared to controls. The concentrations of haptoglobin and Apo A IV were higher in the confirmed cases of GBS as compared to the control subjects, and this difference was found to be significant. The receiver operating characteristic curve analysis for haptoglobin revealed that the area under the curve (AUC) was 0.867 (95% CI: 0.732-1.001), with a sensitivity of 83.8% and a specificity of 63.3%. The AUC for Apo A IV was 0.883 (95% CI: 0.758-1.009), with a sensitivity of 91.7% and a specificity of 73.3%. Haptoglobin along with Apo A IV can emerge as a potential biochemical marker in CSF for the diagnosis of GBS.
Sections du résumé
BACKGROUND
BACKGROUND
Brain- and blood-derived protein analysis in the cerebro-spinal fluid (CSF) in various studies performed abroad found that some proteins and their isoforms were altered significantly in Guillain-Barre´ syndrome (GBS) patients in comparison to controls. However, data are lacking in India with respect to the blood- or brain-derived proteins in patients of GBS.
OBJECTIVE
OBJECTIVE
This study aimed to identify the role of apolipoprotein A IV (Apo A IV) and haptoglobin as potential protein markers in CSF of patients with GBS in our population.
MATERIALS AND METHODS
METHODS
The study comprised 28 participants where 12 confirmed cases of GBS and 16 control subjects admitted for non-infectious neurological disorders were recruited after obtaining approval from the Institutional Ethics Committee. CSF glucose, protein, and adenosine deaminase were analyzed using an autoanalyzer. The concentrations of Apo A IV and haptoglobin were estimated with enzyme-linked immuno-sorbent assay (ELISA) kits.
RESULTS
RESULTS
The CSF protein concentrations of cases were higher as compared to controls. The concentrations of haptoglobin and Apo A IV were higher in the confirmed cases of GBS as compared to the control subjects, and this difference was found to be significant. The receiver operating characteristic curve analysis for haptoglobin revealed that the area under the curve (AUC) was 0.867 (95% CI: 0.732-1.001), with a sensitivity of 83.8% and a specificity of 63.3%. The AUC for Apo A IV was 0.883 (95% CI: 0.758-1.009), with a sensitivity of 91.7% and a specificity of 73.3%.
CONCLUSIONS
CONCLUSIONS
Haptoglobin along with Apo A IV can emerge as a potential biochemical marker in CSF for the diagnosis of GBS.
Identifiants
pubmed: 39041974
doi: 10.4103/neuroindia.NI_1914_20
pii: 02223311-202405000-00017
doi:
Substances chimiques
Haptoglobins
0
Biomarkers
0
apolipoprotein A-IV
0
Apolipoproteins A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
567-571Informations de copyright
Copyright © 2024 Copyright: © 2024 Neurology India, Neurological Society of India.
Références
Burns TM. Guillain-Barré syndrome. Semin Neurol 2008;28:152–67.
Hughes RA, Cornblath DR. Guillain-Barre syndrome. Lancet 2005;366:1653–66.
Hughes RA, Hadden RD, Gregson NA, Smith KJ. Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol 1999;100:74–97.
Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: A systematic review and meta-analysis. Neuroepidemiology 2011;36:123–33.
McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology 2009;32:150–63.
Leonhard SE, Mandarakas MR, Gondim FAA, Bateman K, Ferreira MLB, Cornblath DR, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nat Rev Neurol 2019;15:671–83.
Kuijf ML, van Doorn PA, Tio-Gillen AP, Geleijns K, Ang CW, Hooijkaas H, et al. Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J Neurol Sci 2005;239:37–44.
Jin T, Hu LS, Chang M, Wu J, Winblad B, Zhu J. Proteomic identification of potential protein markers in cerebrospinal fluid of GBS patients. Eur J Neurol 2007;14:563–8.
Zhang HL, Zhang XM, Mao XJ, Deng H, Li HF, Press R, et al. Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-Barr×e syndrome and chronic inflammatory demyelinating polyneuropathy. Acta Neurol Scand 2012;125:129–35.
Chang KH, Lyu RK, Tseng MY, Ro LS, Wu YR, Chang HS, et al. Elevated haptoglobin level of cerebrospinal fluid in Guillain-Barré syndrome revealed by proteomics analysis. Proteomics Clin Appl 2007;1:467–75.
Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27:S21–4.
Hartung HP, Willison HJ, Kieseier BC. Acute immunoinflammatory neuropathy: Update on Guillain-Barré syndrome. Curr Opin Neurol 2002;15:571–7.
Deisenhammer F, Bartos A, Egg R, Gilhus NE, Giovannoni G, Rauer S, et al. Guidelines on routine cerebrospinal fluid analysis: Report from an EFNS task force. Eur J Neurol 2006;13:913–22.
Gonzalez-Quevedo A, Carriera RF, O’Farrill ZL, Luis IS, Becquer RM, Luis Gonzalez RS. An appraisal of blood-cerebrospinal fluid barrier dysfunction during the course of Guillain Barré syndrome. Neurol India 2009;57:288–94.
Canham EM, Iseman MD. Guillain-Barré syndrome related to pulmonary tuberculosis. Ann Am Thorac Soc 2014;11:855–7.
de la Torre RG, Morís G, Martínez DP, Montes IC. Guillain-Barré syndrome, tuberculosis and inflammatory bowel disease: A multiple association. Int Arch Med 2010;3:15.
Soehardy Z, Yuhanisa A, Thein SS, Rohana AG, Fauzi AR, Norlinah MI, et al. AMSAN variant of Guillain Barre syndrome progressing to chronic inflammatory demyelinating polyneuropathy in a patient with Marfan’s syndrome and pulmonary tuberculosis. Med J Malaysia 2005;60:655–6.
Taha AA, Tee KH. Guillain-Barré syndrome associated with pulmonary tuberculosis. BMJ Case Rep 2012;2012:bcr0120125484. doi: 10.1136/bcr-01-2012-5484.
Vyravanathan S, Senanayake N. Guillain-Barré syndrome associated with tuberculosis. Postgrad Med J 1983;59:516–7.
Mohta S, Soneja M, Vyas S, Khot W. Tuberculosis and Guillain-Barre syndrome: A chance association? Intractable Rare Dis Res 2017;6:55–7.
Li P, Wang S, Zhang R, Pei J, Chen L, Cao Y, et al. Identification of CSF biomarkers by proteomics in GuillainBarré syndrome. Exp Ther Med 2018;15:5177–82.
Jain S, Gautam V, Naseem S. Acute-phase proteins: As diagnostic tool. J Pharm Bioallied Sci 2011;3:118–27.
Sainaghi PP, Collimedaglia L, Alciato F, Leone MA, Naldi P, Molinari R, et al. The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barré syndrome from chronic inflammatory demyelinating polyneuropathy. Cytokine 2010;51:138–43.
Li X, Miyajima M, Mineki R, Taka H, Murayama K, Arai H. Analysis of potential diagnostic biomarkers in cerebrospinal fluid of idiopathic normal pressure hydrocephalus by proteomics. Acta Neurochir 2006;148:859–64.
Conti A, Sanchez-Ruiz Y, Bachi A, Beretta L, Grandi E, Beltramo M, et al. Proteome study of human cerebrospinal fluid following traumatic brain injury indicates fibrin (ogen) degradation products as trauma-associated markers. J Neurotrauma 2004;21:854–63.
Pantoni L, Inzitari D. Abnormal penetration of haptoglobin through the blood– brain-barrier (BBB) into the cerebro-spinal fluid (CSF) in Alzheimer’s disease patients. Acta Neurol Scand 1995;91:225.
Chang KH, Tseng MY, Ro LS, Lyu RK, Tai YH, Chang HS, et al. Analyses of haptoglobin level in the cerebrospinal fluid and serum of patients with neuromyelitis optica and multiple sclerosis. Clin Chim Acta 2013;417:26–30.
Stan S, Delvin E, Lambert M, Seidman E, Levy E. Apo A-IV: An update on regulation and physiologic functions. Biochem Biophys Acta 2003;1631:177–87.